On August 13, Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter results that captured a company scaling a genuinely new kind of medicine while working through the bumps that come with it. ZEVASKYN, its cell therapy for a severe skin disease called recessive dystrophic epidermolysis bullosa, brought in $11.4 million in revenue for the quarter, and the number of patients treated kept rising. But the call also laid out cancellations, manufacturing hiccups, and a shift in how the company plans to report its own progress, all within the same three months.
Bull Case: Patients Multiply, Access Widens
Revenue climbed 31%, or $2.7 million, to $11.4 million from $8.7 million in the first quarter of 2026. Abeona has now treated 12 patients since ZEVASKYN’s launch, including five in the second quarter and three more in the third quarter to date. The treatment center network grew alongside that, reaching seven activated sites with the recent addition of Cincinnati Children’s, one of the largest epidermolysis bullosa treatment hubs in the country. New York-Presbyterian/Columbia University Irving Medical Center and Children’s Hospital of Philadelphia also came online during the quarter, and CHOP moved fast, completing its first treatment in July just months after activating in May. UTMB, meanwhile, finished its first patient biopsy. Roughly 40% of the addressable patient population now has in-state access to a qualified treatment center.
Abeona also picked up a new technology add-on payment from the Centers for Medicare and Medicaid Services, effective Oct. 1, 2026, for fiscal year 2027, making it one of only three approvals out of 15 new applications that cycle. On the cost side, R&D spending fell to $5 million from $9.6 million, which had included a one-time $7 million licensing payment, and SG&A dropped to $15.8 million from $19.5 million. The company closed the quarter with $146.8 million in cash and short-term investments.
Bear Case: Growing Pains Behind The Scenes
The net loss widened to $20.2 million, or $0.35 per share, from $17.1 million, or $0.30 per share, in the first quarter. Of the five patients treated in the second quarter, only four generated recognized revenue, because one batch’s cell yield came in below the threshold required for recognition. Management pointed to ZEVASKYN’s 84-hour shelf life as a core operational challenge, since it forces dermatologists, surgeons, anesthesiologists, and hospital staff to lock in exact dates well ahead of time. That rigidity showed up directly in the numbers: two scheduled biopsies were canceled at the last minute in the second quarter after patients’ health unexpectedly declined, and because those slots had been booked so far in advance, they could not be filled by another patient.
Manufacturing added its own complication, with one low-yield batch in the second quarter and one out-of-specification batch in the third quarter, neither generating revenue even though both patients were still treated. Abeona is also changing its disclosure approach, moving away from reporting leading indicators like scheduled or in-manufacturing biopsies and toward reporting only patients treated and revenue recognized within a given quarter.
Wall Street Still Split
Hedge fund ownership slipped to 23 funds holding a position, down from 25 the prior quarter, a modest pullback rather than a rush for the exits. Short interest, meanwhile, sits at 25.69% of the float, a level that reflects a substantial pocket of organized skepticism toward the stock. That combination suggests the market remains genuinely undecided on how to weigh ZEVASKYN’s early commercial progress against its operational stumbles.
Where The Story Heads Next
Abeona now has real revenue, a growing treatment network, and a fresh reimbursement win in NTAP status, all signs that ZEVASKYN has moved past the pure science-experiment phase. Yet the same quarter that produced those milestones also produced a wider net loss, a batch that missed revenue thresholds, and biopsy cancellations tied to factors outside the company’s control. For the bullish case to keep building, QTC activations and physician confidence need to translate into a steadier, larger flow of treated patients each quarter. For the more cautious view to ease, Abeona will need to show that yield problems and scheduling disruptions shrink as the network matures rather than recurring as a permanent cost of doing business.
While we acknowledge the risk and potential of ABEO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABEO and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center